PRISAR - Preclinical Intraoperative Image-Guided Surgery and Postoperative Radiotherapy of Tumours
    Positive patient outcome: better overall survival and quality of life for the patient:
    · Quality of life - less invasive surgery or personalized medicine approaches.
    · Economic - avoid unnecessary or less invasive surgery which leads to reduced hospital stays, less complications and lower reoperation rates due to better margin detection and smaller damage of healthy tissue.
    · Reduce the chances of recurrence - enable post-resection radiotherapy, enable complete tumour resection.
    Improved accuracy during and after tumour surgery: well-defined objectives:
    · Fluorescence - visibly distinct tumour against a background of healthy tissue during the operation.
    · Targeting - precision surgery, aiming at complete resection of the tumour.
    · Molecular radiotherapy - postoperative intracavitary targeted treatment.
    · Standardisation - towards a gold standard to give a new definition of what represents a clear tumour margin.
    Image-guided surgery requires:
    · Hybrid fluorescence-labelled intraoperative tumour-margin specific probe and postoperative targeted radiotherapy.
    · Hybrid optoacoustic equipment to visualise deep-seated tumours.
    · High resolution, sensitivity and functional contrast.